Recludix Pharma said Chief Executive Officer Nancy Whiting, Pharm.D., and President and Head of Research and Development Ajay Nirula, M.D., Ph.D., will present an overview of the company at the Stifel 2026 Virtual Immunology and Inflammation Forum on Sept. 24, 2026, at 3:30 p.m. Eastern Time. A live and archived webcast will be available through the News & Events page of Recludix’s website. The clinical-stage company uses custom-generated DNA-encoded libraries, parallel structure-activity relationship analysis and a proprietary screening tool to discover potent, selective inhibitors of challenging protein targets. Its lead development work focuses on SH2 domain inhibitors, including the oral STAT6 inhibitor REX-8756, also known as SAR448755, which is in a Phase 1 study under a strategic development and commercialization partnership with Sanofi. Recludix has an option to participate in an equal U.S. profit/loss share. The company is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell- or mast cell-driven inflammatory and immunology diseases, alongside additional discovery programs.